Literature DB >> 32242850

RISK-FACTORS OF CORONARY ARTERY DISEASE (REVIEW).

M Kantaria1, M Buleishvili2, Nina V Kipiani3, G Ormotsadze4, T Sanikidze3.   

Abstract

The treatment of coronary arteries disease (CAD) and the prevention of their complications, intervention on the coronary arteries is usually recommended. In this review, with the aim of improving the treatment outcomes of patients with CAD, requiring percutaneous coronary intervention and/or coronary artery bypass grafting,risk factors of developing coronary syndrome are discussed. Understanding the causes of the disturbance of coronary artery conduction will provide a new perspective for improving patient treatment outcomes. Revascularization cannot protect against future acute thrombotic events; for the successful treatment of CAD combining optimal revascularization strategies with long-term measures of risk reduction in lifestyle, often in combination with pharmacological measures, is needed. Numerous primary and secondary prevention trials have shown that management of modifiable risk factors (reduction in LDL-cholesterol level, decrease in blood pressure, discontinuation of smoking) reduces death rates, myocardial infarction, stroke, and other cardiovascular events, including the need for revascularization. Refined guidelines for the primary and secondary prevention of atherosclerosis account for modifiable and nonmodifiable, and other emerging risk factors of CAD.

Entities:  

Year:  2020        PMID: 32242850

Source DB:  PubMed          Journal:  Georgian Med News        ISSN: 1512-0112


  2 in total

1.  Missense Variant rs28362680 in BTNL2 Reduces Risk of Coronary Heart Disease.

Authors:  Jian Zhuo; Yingchun Wu; Wei Li; Zerong Li; Yipeng Ding; Tianbo Jin
Journal:  Pharmgenomics Pers Med       Date:  2022-05-06

Review 2.  Effect of cigarette smoking on coronary arteries and pattern and severity of coronary artery disease: a review.

Authors:  Nahid Salehi; Parisa Janjani; Hooman Tadbiri; Mohammad Rozbahani; Milad Jalilian
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.